Endocrine Abstracts

Introduction: PRES it’s a neurologic syndrome with multiple manifestations, that includes high blood pressure with a variable range. It usually develops in the context of medications or an underlying condition. The treatment is usually symptomatic and determined by said disease.Objective: We present the case of a patient with PRES linked to the diagnostic of a metastatic PHEO.Case-report: A 72-year-old male underwent left adre...

Introduction: Several studies have demonstrated a high incidence of vertebral fractures (VF) in acromegaly, not always correlated with bone mineral density (BMD) value adquired by dual X-ray absorptiometry (DEXA). At trabecular level, GH may alter bone microarchitecture (BM) that predisposes to bone fragility. Trabecular Bone Score (TBS), a textural parameter applied to DEXA to evaluate BM, could be useful to predict VF risk in these patients.Materials a...

Aim: Evaluate the predictive value of the Pituitary Apoplexy Score (PAS) for predicting hormonal and visual recovery after surgery or conservative management of patients with pituitary apoplexy (PA).Methods: Multicenter retrospective study of patients presenting with clinical PA in three Spanish tertiary hospitals between 2008 and 2022. The PAS was calculated following the UK Pituitary Apoplexy Guidelines Development Group evaluation grid.<p class="a...

Introduction / Background: Patients with advanced GEP-NENs often present with metabolic disorders and oncological treatments may increase malnutrition risk as well as alterations on body composition. Several studies have suggested that sarcopenia is independently associated with a worse prognosis in oncological patients. Sarcopenia predicts survival regardless of body weight; moreover, a reduced muscle mass is not only observed in cachectic individuals but also in overweight p...

We previously described a short version of the acute octreotide test (sAOT) for predicting somatostatin receptor ligands (SRLs) response in patients with acromegaly1. In the present work, we prospectively reassess the sAOT ability to identify SRLs response in patients from the ACROFAST study using the current GH standards and control criteria and we also correlate sAOT values with E-cadherin tumor expression. Methods: Patients from the ACROFAS...